Abbott Laboratories Corporation

Anthony Scott Muerhoff

Suresh M Desai

George J Dawson

Thomas P Leary

Isa K Mushahwar

Larry G Birkenmeyer

John N Simons

Tami J Pilot-Matias

James Carl Erker

George G Schlauder

Sheri L Buijk

Bruce J Dille

David J Hawksworth

Robert N Ziemann

Susan E Brophy

Bryan C Tieman

Bailin Tu

Barry Lee Dowell

John C Prostko

Carol S Ramsay

Cheng Zhao

Philip M Hemken

Carolyn J Strobel

Christopher C Marohnic

Ruthie E Coffey

Mark A Hayden

Andrew G Fischer

Jeffrey B Huff

Dinesh O Shah

Qiaoqiao Ruan

Sergey Y Tetin

Mark R Pope

Robin A Gutierrez

James L Stewart

Sophie Laurenson

Shelley R Holets-McCormack

Robert J Carrick

Pathik H Soni

Lyle Yarnell

Dustin House

Edna Prieto-Ballengee

Peter J Karabatsos

Lei Qiao

M Felicia Bogdan

Richard Haack

Teresa K Surowy

Michelle Chalmers

Stefan Hershberger

Chris Marohnic

M Shawn Murphy

Xingli Jiang

Andrew S Schapals

Andrew T Fischer

Edna M Prieto-Ballengee

Felicia Bogdan

Thomas Leary

Barry L Dowell

Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.

Anti-GP73 monoclonal antibodies and methods of obtaining the same

The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a 'double shot' of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).

Subject anti-HCV antibody detection assays employing NS3 capture peptides

Methods, devices, and systems for analyte analysis using a nanopore are disclosed. The methods, devices, and systems utilize a first and a second binding member that each specifically bind to an analyte in a biological sample. The method further includes detecting and/or counting a cleavable tag attached to the second binding member and correlating the presence and/or the number of tags to presence and/or concentration of the analyte. Certain aspects of the methods do not involve a tag, rather the second binding member may be directly detected/quantitated. The detecting and/or counting may be performed by translocating the tag/second binding member through a nanopore. Devices and systems that are programmed to carry out the disclosed methods are also provided.

Devices and methods for sample analysis

The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of, and methods of using these polynucleotides and polypeptides in the detection ofantibodies or anti-antibodies in a subject. The invention finds particular useful application in identifying recent exposure to

[object Object]

The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of thespeciesand. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.

The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of thespeciesandSuch genes and proteins have many beneficial diagnostic as well as therapeutic uses.

The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply.

Methods for the simultaneous detection of HCV antigens and HCV antibodies

Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.

Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use

Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use

Growing community of inventors

Kenosha, WI, United States of America

Anthony Scott Muerhoff